human immunodeficiency virus infection MedDRA version: 16.1 Level: PT Classification code 10020161 Term: HIV infection System Organ Class: 10021881 - Infections and infestations
Conditions
Interventions
Product Name: MK-0518 (reformulated raltegravir)
Product Code: MK-0518
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: RALTEGRAVIR
Sponsors
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male or female at least 18 years of age 2. Understand the study procedures, be able to compile with the study procedures, and voluntarily agree to participate by giving written informed consent for the trial and for Future Biomedical Research (not required to participate). 3. HIV-1 positive as determined by a positive result by enzyme-immunoassay and have screening plasma HIV-1 RNA (determined by the central laboratory) =1000 copies/mL within 45 days prior to the treatment phase of this study. 4. Naïve to ART including investigational ART agents. 5. The following screening laboratory values: Serum creatinine =2.0 x ULN; Alkaline phosphatase =3.0 x ULN; AST (SGOT) and ALT (SGPT) =5.0 x ULN; calculated creatinine clearance = 30 mL/min. 6. Clinically stable with no signs or symptoms of active infection. 7. Agree to one of the following if of reproductive potential: 1) True abstinence or 2) Use of an acceptable method of birth control throughout the study (either by subject or subject’s partner). Acceptable methods of birth control are: oral contraceptives, intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, condom, vasectomy (All forms of hormonal contraception are acceptable). Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 745 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 5
Exclusion criteria
Exclusion criteria: 1. A history or current evidence of any condition, therapy, laboratory abnormality or other circumstance (ex. recreational or illicit drug use or alcohol abuse or dependence) that might confound the results of the study, or interfere with the subject’s participation for the full duration of the study, such that it is not in the best interest of the subject to participate. 2. Has been treated for a viral infection other than HIV-1, such as hepatitis B, with an agent that is active against HIV-1 including but not limited to adefovir, tenofovir, entecavir, emtricitabine, or lamivudine. 3. Documented or known resistance to raltegravir, emtricitabine, and/or tenofovir prior to the treatment phase of the study. 4. Participated in a study with an investigational compound/device within 30 days of signing informed consent or anticipates participating in such a study involving an investigational compound/device during the course of this study. 5. Use of systemic immunosuppressive therapy or immune modulators within 30 days prior to treatment in this study or is anticipated to need them during the course of the study. 6. Requires or is anticipated to require prohibited medications while in the study. 7. Has significant hypersensitivity or other contraindication to any of the components of the study drugs. 8. Current (active) diagnosis of acute hepatitis due to any cause. 9. Is pregnant, breastfeeding, or expecting to conceive at any time during the study. 10. A female expecting to donate eggs at any time during the study or is a male expecting to donate sperm at any time during the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Evaluate the efficacy of reformulated raltegravir 1200 mg q.d. plus TRUVADA, compared to raltegravir 400 mg b.i.d. plus TRUVADA, measured by the proportion of subjects with HIV-1 RNA <40 cp/mL at Week 48.;Primary end point(s): Proportion of Subjects Achieving HIV-1 RNA < 40 copies/mL;Timepoint(s) of evaluation of this end point: Week 48 and Week 96;Secondary Objective: Evaluate the efficacy of reformulated raltegravir 1200 mg q.d. plus TRUVADA, compared to raltegravir 400 mg b.i.d. plus TRUVADA, measured by proportion of subjects with HIV-1 RNA <40 cp/mL at Week 96, and change from baseline in CD4 cell count at Week 48 and Week 96. Evaluate the safety and tolerability of reformulated raltegravir 1200 mg q.d. plus TRUVADA, compared to raltegravir 400 mg b.i.d. plus TRUVADA, by review of the accumulated safety data at Week 48 and Week 96. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Efficacy: Change from Baseline in CD4 Cell Count Safety: Adverse Experiences and Predefined Limits of Change (PDLOC) ;Timepoint(s) of evaluation of this end point: Week 48 and Week 96 | — |
Countries
Argentina, Australia, Belgium, Brazil, Canada, Chile, Colombia, France, Germany, Guatemala, Israel, Italy, Korea, Republic of, Malaysia, Mexico, Philippines, Portugal, Russian Federation, South Africa, Spain, Switzerland, Taiwan, Thailand, United Kingdom, United States
Contacts
Public ContactDivisione Ricerca Clinica
MSD Italia S.r.l.
Outcome results
None listed